Search
On July 21, Dongyang Yangtze River Pharmaceutical (01558.HK) successfully secured overwhelming approval for its merger plan at its Extraordinary General Meeting. This landmark event marks the first instance of an H-share company undergoing a merger and privatization process followed by a subsequent listing on the Hong Kong Stock Exchange. Dongyang Guangyao is scheduled to officially debut on the main board of the Hong Kong Stock Exchange on August 7, setting a new benchmark for the asset securitization of innovative pharmaceutical enterprises in China. As a comprehensive innovative pharmaceutical company, Dongyang Guangyao embarks on this innovative asset securitization journey to tap into the capital market, with the aim of accelerating its international expansion.
-
C114 Communication Network -
Communication Home
